Decoy Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Decoy Therapeutics Inc. (DCOY) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $212.55 thousand for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-07-17.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2019-07-17
- Decoy Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2019-06-30 was $212.55K, a 58.41% decline year-over-year.
- Decoy Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2019-03-31 was $220.97K, a 75.69% decline year-over-year.
- Decoy Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2018-06-30 was $510.99K.
- Decoy Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2018-03-31 was $908.94K.
- Decoy Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $1.94M, a 54.03% decline from fiscal 2017.
- Decoy Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2017 was $4.22M, a 35.81% decline from fiscal 2016.
- Decoy Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2016 was $6.57M, a 0.37% decline from fiscal 2015.
- Decoy Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2015 was $6.60M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 10 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2019-06-30 | $212.55K 10-Q · filed 2019-07-17 | $433.52K derived: sum of 2 quarters · filed 2019-07-17 | ||
| 2019-03-31 | $220.97K 10-Q · filed 2019-07-17 | |||
| 2018-12-31 | $1.94M 10-K · filed 2019-03-06 | |||
| 2018-06-30 | $510.99K 10-Q · filed 2019-07-17 | $1.42M derived: sum of 2 quarters · filed 2019-07-17 | ||
| 2018-03-31 | $908.94K 10-Q · filed 2019-07-17 | |||
| 2017-12-31 | $4.22M 10-K · filed 2019-03-06 | |||
| 2016-12-31 | $6.57M 10-K · filed 2019-03-06 | |||
| 2015-12-31 | $6.60M 10-K · filed 2018-03-07 | |||
| 2014-12-31 | $1.46M 10-K · filed 2017-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |